|
Click here to view online. Add this email to your safelist. |
|||||||||||
|
|
|||||||||||
|
Breztri Aerosphere Phase III ETHOS trial met its primary endpoint in chronic obstructive pulmonary disease |
|||||||||||
|
|
|||||||||||
|
28 August 2019
AstraZeneca today announced positive results from the Phase III ETHOS trial for triple-combination therapy Breztri Aerosphere, formerly PT010, in patients with moderate to very severe chronic obstructive pulmonary disease (COPD). |
|||||||||||
|